The utility of prostate-specific antigen in the management of advanced prostate cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The utility of prostate-specific antigen in the management of advanced prostate cancer
Authors
Keywords
-
Journal
BJU INTERNATIONAL
Volume 112, Issue 5, Pages 548-560
Publisher
Wiley
Online
2013-07-04
DOI
10.1111/bju.12061
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force
- (2013) Roger Chou et al. ANNALS OF INTERNAL MEDICINE
- 918 Prostate-specific antigen kinetics in patients with bone metastases from castration-resistant prostate cancer receiving zoledronic acid therapy
- (2012) F. Saad et al. EUROPEAN UROLOGY SUPPLEMENTS
- Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
- (2012) M. L. Huber et al. JNCI-Journal of the National Cancer Institute
- Role of Testosterone in Managing Advanced Prostate Cancer
- (2012) Kyle O. Rove et al. UROLOGY
- Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy
- (2011) Shu-Pin Huang et al. Aging Male
- The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
- (2011) Emmanuel S. Antonarakis et al. BJU INTERNATIONAL
- The basis for monitoring strategies in clinical guidelines: a case study of prostate-specific antigen for monitoring in prostate cancer
- (2011) J. Dinnes et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
- (2011) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2011) Nicolas Mottet et al. EUROPEAN UROLOGY
- Missing the Mark on Prostate-Specific Antigen Screening
- (2011) David C. Miller et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice
- (2011) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials
- (2011) Anthony V D'Amico et al. LANCET ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy
- (2011) Shu-Pin Huang et al. PROSTATE
- Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: Clinical factors associated with PSA response and disease progression
- (2011) Daniel Keizman et al. PROSTATE
- The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation
- (2011) Daniel Keizman et al. PROSTATE
- Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis
- (2011) T Sasaki et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy
- (2011) S Miyamoto et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database
- (2010) Emmanuel S. Antonarakis et al. BJU INTERNATIONAL
- Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer
- (2010) Matthew R. Smith et al. CANCER
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease
- (2010) Axel Heidenreich et al. EUROPEAN UROLOGY
- Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer
- (2010) S. Hori et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent Androgen Deprivation
- (2010) Evan Y. Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu
- (2010) Itsuhiro Takizawa et al. PROSTATE
- Small Cell Carcinoma of the Prostate
- (2009) Wenle Wang et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Prostate-specific antigen kinetics in localized and advanced prostate cancer
- (2009) John M. Fitzpatrick et al. BJU INTERNATIONAL
- Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy
- (2009) Toni K. Choueiri et al. CANCER
- Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: Predictive factors
- (2009) Seung Chol Park et al. INTERNATIONAL JOURNAL OF UROLOGY
- Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer
- (2009) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
- (2009) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial
- (2009) Michael E. Ray et al. JNCI-Journal of the National Cancer Institute
- Prostate Specific Antigen Half-Time and Prostate Specific Antigen Doubling Time as Predictors of Response to Androgen Deprivation Therapy for Metastatic Prostate Cancer
- (2009) Yong Hyun Park et al. JOURNAL OF UROLOGY
- From pathogenesis to prevention of castration resistant prostate cancer
- (2009) Helmut Bonkhoff et al. PROSTATE
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
- (2008) Laurence Klotz et al. BJU INTERNATIONAL
- Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer
- (2008) Robert W. Ross et al. CANCER
- Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer
- (2008) J. A. Locke et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
- (2008) D. R. Berthold et al. CLINICAL CANCER RESEARCH
- Undetectable Level of Prostate Specific Antigen (PSA) Nadir Predicts PSA Biochemical Failure in Local Prostate Cancer with Delayed-combined Androgen Blockade
- (2008) N. Soga et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer
- (2008) Andrew J. Vickers et al. JOURNAL OF CLINICAL ONCOLOGY
- Alternative Nonsteroidal Antiandrogen Therapy for Advanced Prostate Cancer That Relapsed After Initial Maximum Androgen Blockade
- (2008) Hiroyoshi Suzuki et al. JOURNAL OF UROLOGY
- Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time
- (2008) Philip M. Arlen et al. JOURNAL OF UROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now